Abstract
disease (IBD). CD has progressive character and is associated with the development of various complications leading to potentially serious bowel damage (BD). Early stage of Crohn’s disease (eCD) is characterized by a specific immune response and represents an attractive target for specific agressive therapy. The use of biologics (BL) in eCD may help to prevent BD and allow early dose reduction or even discontinuation of BL. Wide scientific evidence supports the importance of BL in eCD based on studies with anti-TNF biologics (being part of clinical practice for relatively long time now). However, studies on novel biologics with low rate of the adverse events (vedolizumab, ustekinumab) also show promising results. Defining high-risk groups and suitable biomarkers would help to select those eCD patients who would benefit the most from early biological therapy. Key words: inflammatory bowel disease – Crohn’s disease – biological therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
